Edaravone is a medication used to treat certain conditions like ALS and stroke. It works by helping to protect nerve cells from damage caused by free radicals. It's taken as a pill.
Every report comes from a Lived member, sent anonymously.
Have you tried Radicava (Edaravone) for ALS?
Edaravone, sold as Radicava, is a prescription medicine for amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease), a condition in which the nerve cells that control voluntary muscles gradually die, leading to weakness that spreads over time. In the US, ALS is its only approved use. It comes in two forms: Radicava, an intravenous (IV) infusion given into a vein, and Radicava ORS, an oral suspension (a liquid) that can be swallowed or given through a feeding tube. Generic edaravone injections are also available. Edaravone does not cure ALS or restore strength that has been lost. Its aim is to slow the loss of everyday physical function. It is often used alongside riluzole, an older ALS medicine, and alongside the supportive care that remains central to living with ALS.
Edaravone is an antioxidant, a type of compound that neutralizes free radicals. Free radicals are unstable molecules produced during normal metabolism; when they build up faster than the body can clear them, they damage cells. This kind of damage, called oxidative stress, is thought to be one of several processes that contribute to the death of motor nerve cells in ALS. The idea is that by mopping up free radicals, edaravone may slow that nerve damage. However, the drug's official labeling states that exactly how it benefits people with ALS is unknown, and ALS has many contributing causes that edaravone does not address.
Both forms follow the same on-and-off schedule. The first cycle is a dose every day for 14 days, then 14 days with no medicine. After that, each cycle is a dose on 10 of 14 days, followed by another 14-day break. A study comparing daily oral doses with this schedule found that taking it every day worked no better. The IV form is given as an infusion lasting about an hour, usually at an infusion center or at home with a visiting nurse. Because treatment days are frequent, many people have a port or other long-term IV line placed, which adds its own care and infection risk. The oral suspension is taken in the morning on an empty stomach after an overnight fast, measured with the oral syringe that comes with it, and nothing but water should be eaten or drunk for 1 hour afterward. Food matters a great deal here: taking it soon after a high-fat meal sharply reduces how much medicine is absorbed. The labeling gives specific waiting times (for example, 8 hours after a high-fat meal or 2 hours after a protein drink), so it helps to plan meals and tube feedings around the dose. People already on the IV form can usually switch to the oral form on the same schedule.
In clinical trials, the side effects reported more often with edaravone than with placebo were bruising, walking difficulties and headache, followed by skin problems such as eczema and rash. Fatigue was reported by some people taking the oral form. Because ALS itself causes weakness and falls, it can be hard to tell which of these problems come from the medicine and which from the disease. Allergic reactions, though uncommon, are the main serious risk. A new rash or skin redness should be reported to the prescriber before the next dose. Hives with trouble breathing, wheezing, throat or facial swelling, or feeling faint is a possible anaphylaxis (a severe, whole-body allergic reaction): call 911. People using a port or IV line should also contact their care team promptly about fever, or redness, swelling, pain or drainage at the line site.
Edaravone should not be used by anyone who has had an allergic reaction to edaravone or to any of the inactive ingredients in the product. Both the IV and oral forms contain sodium bisulfite, a sulfite preservative that can cause allergic reactions and asthma attacks in sensitive people. Sulfite sensitivity is more common in people with asthma, so mention asthma or any past reaction to sulfites before starting. No specific drug interactions are listed in the US labeling, but the care team should still know every prescription, over-the-counter medicine and supplement being used. There is little information about edaravone in pregnancy, and animal studies at relevant doses showed harm to developing offspring. It is also unknown whether it passes into human breast milk. Anyone who is pregnant, planning a pregnancy or breastfeeding should talk this through with the prescriber.
Edaravone is not expected to make anyone feel stronger or to stop ALS. In the main trial, people early in ALS lost function more slowly over six months than those on placebo. That trial measured function with the ALS Functional Rating Scale-Revised (ALSFRS-R), a 48-point questionnaire covering speech, swallowing, hand use, walking and breathing, where higher scores mean more ability. Over six months, people on edaravone lost about 5 points and those on placebo about 7.5 points. That result came from a carefully selected group: people living independently, with near-normal breathing and function, diagnosed within the previous two years. How well it works for people with more advanced or slower-moving disease is less certain. A large study of patients treated in German ALS clinics found no clear slowing of progression, survival or need for breathing support compared with similar patients not taking it. Some specialists therefore see the benefit as modest and uncertain, while others continue to offer it, especially early in the disease. Because no one can feel the effect directly, response is judged over months through regular clinic visits, ALSFRS-R scores and breathing tests. Many people weigh the possible benefit against the time involved, IV access or fasting rules, and cost and insurance requirements. Deciding to continue or stop is a reasonable conversation to revisit as the disease changes.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Radicava (Edaravone), what you've noticed, or ask the community a question.